Top assists from Brooklyn Nets vs. Dallas Mavericks, 02/27/2021
Top assists from Brooklyn Nets vs. Dallas Mavericks, 02/27/2021
President Biden delivers remarks from the White House about coronavirus vaccinations and the administration’s response to the pandemic.
Surge testing is being deployed in parts of Birmingham after a case of the South African variant was discovered. Areas of Alum Rock and Glebe Farm & Tile Cross have been targeted for testing and all those in the affected places are being told to come forward for a test. The person who tested positive for the variant has gone into self-isolation and their contacts have been identified, according to the Department of Health.
Mike and Zara Tindall were able to attend the funeral of her grandfather Philip at the weekend.
The bullets were fired by people arguing in the neighborhood
OnePlus is rolling out an update that should improve activity tracking.
Imax has partnered with Imagine Documentaries, the non-fiction division of the entertainment company founded by Ron Howard and Brian Grazer, to produce and distribute its next five films. The upcoming slate deal covers topics including space, exploration, natural sciences and more. In addition to co-financing the titles, Imax will screen the movies in its high-quality […]
UK inquiry blames ‘pervasive racism’ for unequal commemoration of black and Asian troops. Exclusive: Commonwealth War Graves Commission expected to apologise for commemorating British empire’s black and Asian first world war dead ‘unequally’
How millions of black and Asian men were mobilised in first world war. Many in Africa were recruited forcibly, while Indian army provided 1.2 million soldiers
Going to hell has been a heaven-sent mission for Tanu Muino. She co-directed the year’s — and maybe the young decade’s — most talked about music video, “Montero (Call Me By Your Name),” with its controversial star Lil Nas X. That came right on the heels of directing a video for one of 2021’s other […]
When Sierra Teller Ornelas was in pre-production on her new Peacock comedy “Rutherford Falls,” she found inspiration in a quote she read from showrunner Prentice Penny describing his movie “Uncorked” as “This is Black people on a Tuesday.” The film, which follows a young man on his quest to become a master sommelier, did not […]
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (“Brunswick”) (TSX-V: BRW) and Osisko Metals Incorporated (“Osisko Metals”) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) announce that, following a TSX-V review, they have amended the terms of the option agreement (the “Option”) previously announced on August 17, 2020 whereby Brunswick can acquire a majority interest in Osisko Metals’ Brunswick Belt exploration property (the “Property”), located in the eastern portion of the Bathurst Mining Camp in the Bathurst area in New Brunswick (the “Transaction”). The Property covers 72 kilometres of the prolific Brunswick Belt and includes the Key Anacon and Gilmour South base metal deposits. The amended Option now allows Brunswick to earn up to 51% interest by spending an aggregate of $10,000,000 in two stages over a five-year period. Amended Option Agreement Details The Option is divided into two distinct earn-in requirements (all amounts in Canadian dollars): The First Option: by funding an aggregate of $2,000,000 on or before the second-year anniversary of the signing of the Option and completing a cash payment of $100,000, Brunswick can earn an initial 15% interest in the Property.The Second Option: by funding an aggregate of $10,000,000 (inclusive of First Option expenditures) according to the schedule below, Brunswick can earn an additional 36% interest in the Property for a total interest of 51%: An aggregate of $2,000,000, on or before the 2nd year anniversary;An aggregate of $4,000,000, on or before the 3rd year anniversary;An aggregate of $6,500,000, on or before the 4th year anniversary; andAn aggregate of $10,000,000, on or before the 5th year anniversary. Once any one of the two earn-in requirements are met (as per Brunswick’s discretion), a joint venture can be formed between Brunswick and Osisko Metals. An NI 43-101 independent geological report was completed by John Langton, P. Geo., of JPL GeoServices and was filed by Brunswick on SEDAR on November 5, 2020. Robert Wares is Chairman of the Board and Chief Executive Officer of both Osisko Metals and of Brunswick, and hence abstained from the negotiation process between the two companies. The Transaction constitutes a “Related Party Transaction” within the meaning of the policies of the TSX Venture Exchange (“TSX-V”), as it involves “Non-Arm’s Length Parties”, as defined in such policies. The Transaction is an arm’s length transaction within the meaning of applicable securities laws. The Transaction is conditional upon TSX-V’s final approval. About Osisko Metals Osisko Metals Incorporated is a Canadian exploration and development company creating value in the base metal space. The Company controls one of Canada’s premier past-producing zinc mining camps, the Pine Point Project, located in the Northwest Territories for which the 2020 PEA has indicated an after-tax NPV of $500M and an IRR of 29.6%. The Pine Point Project PEA is based on current Mineral Resource Estimates that are amenable to open pit and shallow underground mining and consist of 12.9Mt grading 6.29% ZnEq of Indicated Mineral Resources and 37.6Mt grading 6.80% ZnEq of Inferred Mineral Resources. Please refer to the technical report entitled “Preliminary Economic Assessment, Pine Point Project, Hay River, North West Territories, Canada” dated July 30, which has been filed on SEDAR. The Pine Point Project is located on the south shore of Great Slave Lake in the Northwest Territories, near infrastructure, paved highway access, and has an electrical substation as well as 100 kilometres of viable haulage roads already in place. The current Mineral Resources mentioned in this press release conform to NI43-101 standards and were prepared by independent qualified persons, as defined by NI43-101 guidelines. The abovementioned Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. The quantity and grade of the reported Inferred Mineral Resources are conceptual in nature and are estimated based on limited geological evidence and sampling. Geological evidence is sufficient to imply but not verify geological grade and/or quality of continuity. Zinc equivalency percentages are calculated using metal prices, forecasted metal recoveries, concentrate grades, transport costs, smelter payable metals and charges (see respective technical reports for details). About Brunswick The Corporation, formerly Komet Resources Inc., is part of the Osisko Group of companies and is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. It is focused on exploration and development of gold and base metal properties in Eastern Canada. Current projects include gold-polymetallic vein systems in southern New Brunswick (Fundy Gold Project), base metals VMS in northern New Brunswick (Bathurst Mining Camp option) and in the Chibougamau region of Quebec (Waconichi), and nickel-copper-cobalt in Quebec (Lac Édouard). For further information on this press release, contact: Osisko MetalsRobert Wares, CEOOsisko Metals IncorporatedEmail: email@example.comBrunswickKillian Charles, PresidentBrunswick Exploration Inc.Email: firstname.lastname@example.org Cautionary Statement on Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates; the preliminary nature of metallurgical test results; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Company’s public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
"Makeup can become a crutch and way to hide."
Influencer and model Rocky Barnes talks about striking the balance between work and motherhood.
Scott Crockett, Everest Business Funding’s Founder and CEO, comments on the recent recognition his company earned as one of the “Best and Brightest Companies to Work for in the Nation.”Doral, FL, April 21, 2021 (GLOBE NEWSWIRE) -- Scott Crockett, Everest Business Funding’s Founder and CEO, was honored and humbled to receive the “Best and Brightest Companies to Work for in the Nation” award recently. The award recognizes organizations that promote employees’ success and accomplishments while encouraging community engagement, diversity, and cultural experiences. Everest Business Funding was chosen from an impressive list of over 1,300 companies. “At Everest Business Funding, our team and culture are what drives our success as one of the leading providers of working capital to small and medium-sized businesses throughout the country. This year, more than ever, we couldn’t be more proud of how our team pulled together through these unique times as we worked tirelessly to help our customers navigate the challenges they were dealing with,” mentioned Scott Crocket. Everest Business Funding provides small- and medium-sized businesses with an alternative to traditional bank loans by utilizing merchant cash advances. These cash advances allow small companies to stay afloat when they need a quick, hassle-free funding process. The recent COVID-19 pandemic forced many businesses to shut their doors overnight, which caused financial crises for many small-business owners. Owners running hair salons, restaurants, nightclubs, and dry cleaners, to name a few, needed to find fast and innovative ways to keep their lights on while waiting out lockdowns and restrictions. Everest Business Funding was able to provide hundreds of business owners with the capital necessary to stay afloat. For Scott Crockett, Everest Business Funding needed to practice what it preached during the pandemic and put people first. Everest employees were able to work remotely whenever possible. Additionally, furloughed employees who couldn’t complete their work remotely were kept on the payroll and able to secure select benefits at the company’s expense. It wasn’t just the company’s response to the pandemic that earned it the “Best and Brightest Companies to Work for in the Nation” award, though. The company’s diverse and dynamic team members participate in a company culture that promotes helping others in the community through holiday toy collections and food drives. Employees also enjoy socializing outside of work at concerts, dinner cruises, and sports events. The main priority for Scott Crockett is to motivate team members to further their careers. Many of the members of the management team were promoted from within the company. Everest encourages personal growth and success for all employees so that they will not only feel like part of a team but will also feel like part of a family.Media Contact:Name: Anthony ParkerEmail: Info@everestbusinessfunding.comOrganization: Everest Business Funding Address: 8200 NW 52nd Ter. 2nd FloorDoral, FL 33166Phone number: 888-342-5709
Helen McCrory was a star of screen as well as stage. There was vastly more depth and breadth in her screen work than The Queen and Skyfall, writes Lawrence Jackson
The women’s world hockey championship tournament in Canada has been postponed indefinitely after health officials in Nova Scotia informed the International Ice Hockey Federation the province’s borders are being closed due to COVID-19 concerns, an IIHF official said Wednesday. IIHF chief Rene Fasel confirmed the development to The Associated Press, saying the organization was informed of the province’s decision earlier in the day. Fasel said he was “very disappointed” by the decision, which comes a little over two weeks before the 10-team tournament was set to run in Halifax and Truro from May 6-16.
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of resistance to a targeted therapyCash position of €14.5 million at December 31, 2020 supplemented by €14.7 million in new financing obtained in early 2021 Extended financial visibility through the end of 2022, enabling the expansion of clinical and industrial development of AsiDNA™ Management live webcast today at 6.30 pm CEST - to participate:https://us02web.zoom.us/webinar/register/WN_T6v8Hc8TRU67rKXPrz2nXw PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today reported its consolidated financial results for the fiscal ending December 31, 2020, and provided a business update. Judith Greciet, Chief Executive Officer of Onxeo, declared: “2020 was marked for all by an unprecedented health crisis. Yet it will have allowed Onxeo to demonstrate the resilience of its teams and strategy. The clinical program for AsiDNA™, our lead candidate, made very significant progress in 2020 on its two development axes, synergy of efficacy with DNA breakers as radio or chemotherapy, and the fight against tumor resistance to targeted therapies. On the first axis, the positive efficacy signals obtained in DRIIV-1b, combining AsiDNA™ with reference chemotherapies, have enabled the preparation of a randomized phase 2 trial in lung cancer. Its adaptive design would allow it to be converted into a pivotal study based on initial positive results. Enrolment will start in the second half of 2021, as soon as regulatory approval is obtained. We have also initiated a Phase 1b/2 pediatric program with the Curie Institute in recurrent high-grade glioma, a brain cancer with a poor prognosis, against which the combination of AsiDNA™ with radiotherapy could offer an efficacy gain. In the fight against resistance to targeted therapies, the Phase 1b/2 Revocan study, which is evaluating the effect of AsiDNA™ on resistance to a PARP inhibitor in ovarian cancer, began in late 2020 and patient enrollment is ongoing. This study is sponsored by Gustave Roussy who leads its management and we expect to receive preliminary results from the first group of patients during the second half of the year. In addition, recent results presented at AACR 2021 confirm the effect of AsiDNA™ on drug-tolerant cells, one of the causes of resistance to targeted therapies such as PARP, KRAS or tyrosine kinase inhibitors. These results provide a strong rationale to consider an expansion of the clinical development of AsiDNA™ in other very high potential combinations. Finally, the OX400 candidates have confirmed in preclinical studies their action on tumor metabolism and the immune system, presaging promising clinical combinations with immunotherapies. This extensive and ambitious R&D program reflects the significant potential of our candidates in multiple combinations and therapeutic areas. Over the past twelve months, we have also significantly strengthened Onxeo's financial and shareholder structure. Invus, an international investor specializing in biotechnology, has joined Financière de la Montagne in the capital and on the Board of Directors of the Company. Their support has contributed to extend our financial horizon to the end of 2022 - well beyond the major clinical milestones expected in the next 18 months - and validates our strategy to expand the clinical and industrial development of our candidates.” FINANCIAL HIGHLIGHTS FOR 2020 Consolidated income statement (IFRS)In thousands of euros 12/31/202012/31/2019Revenues, of which: Recurring revenues Non-recurring revenues1,7761,0776994,2893,455833Operating expenses, of which: R&D expenses (9,803)(3,946)(14,178)(7,718)Other current operating income21395Current operating income / (loss)(7,814)(9,794)Other operating income and expenses10,008(24,543)Share of profit from equity affiliates (39)Operating income/(loss) after share of profit from equity affiliates2,194(34,376)Financial income/(loss)(347)(1,677)Income tax(757)2,324Net profit/loss1,089(33,728) The 2020 consolidated accounts were approved by the board of directors on April 21, 2021. The audit procedures on the consolidated accounts have been carried out. The certification report is in the process of being issued. Revenues for the year 2020 amounted to €1.8 million and include: €1.1 million in recurring revenue corresponding to sales of Beleodaq® under the European Named Patient Program (NPP) and royalties on sales of Beleodaq® in the United States by the partner Acrotech Biopharma. Its decrease from €3.5 million in 2019 is explained by the transfer of this activity to Acrotech as part of the licensing agreement signed in early April 2020.€0.7 million in non-recurring revenue, comprising contractual lump-sum royalties under the business transfer agreement signed in 2017 with Vectans Pharma. Operating expenses amounted to €9.8 million, compared to €14.1 million in 2019. The 31% decrease is mainly related to lower R&D expenses, notably manufacturing operations of AsiDNA™ for clinical trials in 2019, as well as strict management of all the Company's expenses. Other operating income (non-current) amounted to €10.0 million and included the impacts of the agreement with Acrotech Biopharma in April 2020, namely: a net income of 5.7 million euros corresponding to the transaction price of €6.1 million less payments to be made to Acrotech Biopharma for future product development costs estimated at €0.4 million;a charge of 2.8 million euros corresponding to the net book value of the R&D assets related to Beleodaq®/belinostat, reflecting the treatment of the contract with Acrotech under IFRS as a sale agreement;7.1 million euros of proceeds, evaluated on the basis of the financing plan established by management, corresponding to the royalties that the Company expects to receive after the date of signature of the agreement and that are intended to repay the balance of the loan contracted with SWK Holdings Corporation. This amount includes 1.6 million euros of royalties recorded for 2020 after the transaction. The financial result of €-0.3 million is mainly explained by the interest expense related to the bond debt with SWK. The tax charge is €0.8 million and includes deferred taxes of €0.4 million, relating to the royalties the Company expects to receive after December 31, 2020, through which it will repay the balance of the SWK loan. Net income for the year ended December 31, 2020 was a profit of €1.1 million, resulting mainly from the Acrotech transaction and its accounting treatment under IFRS, compared with a loss of €33.7 million for the year ended December 31, 2019 that was linked with a €12.9 million impairment of belinostat-related R&D assets as well as the impacts of the settlement agreement signed with SpePharm early 2020 (-€9.6 million). STRENGTHENED FINANCIAL STRUCTURE As of December 31, 2020, the Company had consolidated cash and cash equivalents of €14.5 million, compared to €5.7 million at the end of fiscal 2019. This sharp increase stems from financing obtained during the year; in particular, the Company completed a private placement in June 2020 with a new investor, Invus Public Equities LP, and Financière de la Montagne, the historical shareholder, for €7.3 million, and it also used the balance of its equity financing line for €3.2 million. The Company also received a payment of $6.6 million in consideration for the granting of additional exclusive rights to belinostat to Acrotech Biopharma LLC in April 2020. The Company's cash position has since been strengthened by obtaining, at the end of January 2021, a €5 million financing in the form of State Guaranteed Loans (SGL) and by the proceeds of the capital increase with shareholders' preferential subscription rights (PSR) finalized on April 12, for a gross amount of €9.7 million. The Company's financial visibility has thus been extended to the end of 2022. FULL-YEAR 2020 HIGHLIGHTS, RECENT DEVELOPMENTS AND OUTLOOK FOR 2021 AsiDNA™ Revocan study At the beginning of 2020, Onxeo launched the Revocan study to evaluate the effect of AsiDNA™ on acquired resistance to a PARP inhibitor (PARPi), in 2nd line recurrent ovarian cancer. This Phase 1b/2 study is sponsored by Gustave Roussy. Enrollment in the study began at the end of 2020 and is continuing, albeit at a slower pace than anticipated, notably due to the epidemic situation. However, it should be noted that as study sponsor, GR is managing the project. Preliminary results of part 1b, initially expected in the first half of the year, are now expected from Gustave Roussy in the second half of the year. The study aims to confirm preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting in June 2020, which showed the ability of AsiDNA™ to reverse PARPi resistance, notably by preventing the regrowth of drug-tolerant cells. DRIIV1-b study - Upcoming phase 2 study Onxeo published favorable interim results from the DRIIV-1b study of AsiDNA™ in combination with standard of care chemotherapies in patients with progressing metastatic tumors in November 2020. Exceptionally long disease control times were observed and are particularly encouraging signals of efficacy. As a result, the Company plans to continue development in this combination in 2021 with a randomized Phase 2 study of AsiDNA™ in non-small cell lung cancer. The adaptive design of this international multicenter study, currently under development, would allow its transformation into a pivotal study. New clinical developments In February 2021, Onxeo entered into a clinical research agreement with Institut Curie, France's leading cancer center, to conduct a Phase 1b/2 study to evaluate the effect of AsiDNA™ in combination with radiotherapy in children with recurrent high-grade glioma (HGG) eligible for re-irradiation. This study is supported by a grant from the European Fight Kids Cancer program and is being conducted as part of the European Innovative Therapies for Children with Cancer (ITCC) consortium. As part of the acceleration of its development, the Company may also file an IND application to expand the clinical program of AsiDNA™ in the United States. INTELLECTUAL PROPERTY In 2020, Onxeo pursued an active policy of industrial protection. The Company received a notice of allowance from the U.S. Patent and Trademark Office for a new patent enhancing the protection of AsiDNA™, which will be valid in the United States until 2037. A notice of intent to issue a new patent enhancing protection in Europe for AsiDNA™ combined with PARP inhibitors was also announced in late October 2020. Onxeo's portfolio of candidates is now protected by several patent families in all territories of interest until 2040. OX400 Onxeo continued preclinical studies of new OX400 candidates, next-generation PARP agonists from its proprietary platON™ platform, in 2020. New results presented at AACR 2021 confirm that by specifically trapping and hyperactivating PARP, OX400 compounds have the potential to modulate the immune response and deplete tumor cell metabolism. The preclinical proof of concept of one or more OX400 compounds, expected in 2021, will be the starting point for the activities necessary for entry into the clinic, potentially in combination with immunotherapy, within 12 to 18 months. CORPORATE & GOVERNANCE In February 2020, Onxeo announced that it had reached an out-of-court settlement agreement with SpePharm and SpeBio. As part of this agreement, Onxeo will pay SpePharm 15 to 20% of the net amounts to be received under future commercial agreements relating to Onxeo's R&D assets, for a total cumulative amount of 6 million euros within a period of 4 years, i.e. at the latest on January 31, 2024. The balance of this debt amounts to 5.1 million euros at December 31, 2020;At its meeting on September 17, 2020, the Board of Directors of Onxeo co-opted Invus Public Equities LP, represented by Mr. Julien Miara, as a director of the Company to replace Mr. Jean-Pierre Kinet, who resigned;In December 2020, Onxeo transferred the listing of its shares from the regulated market of Euronext Paris (compartment C) to the multilateral trading system Euronext Growth Paris. By coherence, Onxeo shares listed in Denmark on the Nasdaq Copenhagen regulated market have been transferred to the Nasdaq First North Growth multilateral trading facility. CONTEXT OF THE COVID-19 PANDEMIC The continuation of the global health crisis linked to the Covid-19 epidemic creates an uncertain situation. Even if Onxeo has been little impacted in 2020, it is difficult to measure the repercussions on the Company's activity and financial situation, which will depend on the intensity and duration of this crisis. The Company has put in place appropriate measures to protect its employees and to ensure the continuity of its operations. It will adapt these measures to the circumstances. The 2020 Financial Report will be available on the Company's website as of April 23, 2021. About Onxeo Onxeo (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline. AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin -/+ paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, stabilization of the disease and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study evaluates the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy). A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to evaluate the association of AsiDNA™ with radiotherapy in children with relapsed high-grade glioma (sponsored by Institut Curie). OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies. For further information, please visit www.onxeo.com. Forward looking statementsThis communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org). Contacts OnxeoValerie Leroy, Investor Relationsinvestors@onxeo.com+33 1 45 58 76 00Media RelationsNicolas Merigeau NewCaponxeo@newcap.eu+33 1 44 71 94 98Investor Relations / Strategic CommunicationDušan Orešanský / Emmanuel Huynh NewCaponxeo@newcap.eu+33 1 44 71 94 92 Certified Adviser for Nasdaq First NorthKapital Partnerwww.email@example.com+45 89 88 78 46 APPENDIX FULL YEAR CONSOLIDATED ACCOUNTS AT DECEMBER 31, 2020 CONSOLIDATED BALANCE SHEET ASSETS in €K12/31/202012/31/2019NoteNon-current assets Intangible assets20,53423,3586Tangible assets831097.1Rights of use2,4792,7187.2Investments in equity affiliates 20 Other financial fixed assets 2331418Total non-current assets23,32926,345 Current assets Inventories and work in progress 64 Trade receivables6,6543,3539.1Other receivables2,0002,1599.2Cash and cash equivalents14,5235,7089.3Total current assets23,17711,284 TOTAL ASSETS46,50637,629 LIABILITIES AND SHAREHOLDERS’ EQUITY K€12/31/202012/31/2019NoteShareholders' equity Capital19,57915,32910.1Less: Treasury shares-182-18910.2Share premium18,57744,92410.3Reserves-10,024-9,13910.3Earnings1,089-33,728 Total shareholders' equity29,03617,197 Non-current liabilities Provisions1,6406,82111.1Deferred tax liability415 16Non-current financial debts4,2787,41211.2Other non-current liabilities5,089 11.3Total non-current liabilities11,42314,233 Current liabilities Short-term borrowings and financial debts1,9791,17012.1Trade payables2,7623,67212.2Other current liabilities1,3061,35812.3Total current liabilities6,0476,199 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY46,50637,629 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME In K€12/31/202012/31/2019NoteRecurring revenue from license agreements1,0773,455 Non-recurring revenues from license agreements699833 Total revenues1,7764,28914.1Purchases-347-350 Personnel expenses-4,265-4,80814.2External expenses-3,882-7,85714.3Taxes and duties-176-127 Net depreciation, amortization and provisions-618-671 Other current operating expenses-515-365 Operating expenses-9,803-14,178 Other current operating income21395 Current operating income-7,814-9,794 Other non-current operating income13,500 14.4Other non-current operating expenses-3,492-24,54314.4Share of profit from equity affiliates -39 Operating income after share of profit of associates2,194-34,376 Cost of net financial debt-958-1,018 Other financial income1,006 Other financial expenses-395-659 Financial income-347-1,67715Tax expenses-7572,32416 - of which deferred taxes-4152,330 Consolidated net income1,089-33,728 Earnings per share0.01(0.55)17Diluted earnings per share0.01(0.55)17 In K€12/31/202012/31/2019Note Result for the period 1,089-33,728 Currency translation differences-7175 Other items recyclable as a result-7175 Actuarial gains and losses-22-54 Other items not recyclable as a result -22-54 Other comprehensive income for the period, net of tax-9321 Total comprehensive income for the period996-33,707 Total comprehensive income attributable to the the parent company owners996-33,707 Minority interests CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Changes in reserves and results In K€CapitalTreasury sharesShare premiumTranslation reservesGains and losses recognized in equityReserves and consolidated resultsTotalDifferencesTOTALShareholders' equity as of 1/01/201913,344-9741,824-109-97-9,462-9,66945,402Total comprehensive income for the period 75-54-33,728-33,707-33,707Capital increase1,986 3,100 05,086Treasury shares -92 -71-71-163Other movements 138138138Share-based payments 441441441Shareholders' equity as of 12/31/201915,329-18944,924-34-151-42,682-42,86817,197Total comprehensive income for the period -71-221,089996996Capital increase4,250 6,230 18818810,668Treasury shares 7 898995Other movements -32,57714 32,56232,577 Share-based payments 797979Shareholders' equity as of 12/31/202019,579-18218,577-91-173-8,674-8,93829,036 CONSOLIDATED STATEMENT OF NET CASH FLOWS K€12/31/202012/31/2019NoteConsolidated net loss1,089-33,728 +/- Depreciation, amortization and provisions, net-8,21525,3946/7/11 (excluding provisions against working capital) +/- Unrealized gain and losses associated with changes in fair value-290484 +/- Non-cash income and expenses on stock options and similar items79441 +/- Other calculated income and expenses +/- Capital gains and losses on disposal57 +/- Dilution gains and losses +/- Share of equity affiliates 39 Gross operating cash flow after cost of net debt and taxes-7,280-7,371 + Cost of net debt9591,03715+/- Tax expenses (including deferred taxes)757-2,32416Gross Operating cash flow before cost of net debt and taxes-5,564-8,658 - Taxes paid +/- Changes in operating WCR (including debt related to employee benefits)886959 NET CASH FLOW FROM OPERATING ACTIVITIES-4,678-7,699 - Expenditures on acquisition of tangible and intangible assets-119-26 + Proceeds of disposal of tangible and intangible assets6,116 - Expenditures on acquisition of financial assets + Proceeds of disposal of financial assets4163 +/- Effect on changes in scope of consolidation14 + Dividends received (equity affiliates, unconsolidated investments) +/- Change in loans and advances granted + Capital grants received +/- Other changes from investment transactions NET CASH FLOW FROM INVESTING ACTIVITIES6,015137 + Net amount received from shareholders on capital increase . Paid by shareholders of the parent company10,5684,74310 . Paid by minority interest in consolidated companies + Amount received on exercise of stock options -/+ Purchase and Sale of treasury shares8 + Amounts received on issuances of new loans - Reimbursements of loans (including lease debts)-3,094-2,72911/12/15o/w repayment of lease debts (IFRS16)-475-452 +/- Others flows related to financing activities-1-1 NET CASH FLOW FROM FINANCING ACTIVITIES7,4812,014 +/- Effects of fluctuations in foreign exchange rates-33 CHANGE IN CASH AND CASH EQUIVALENTS8,815-5,545 CASH AND CASH EQUIVALENTS AT START OF YEAR5,70811,253 CASH AND CASH EQUIVALENTS AT YEAR END14,5235,708
Transparency in aluminum pricing would bring stability for American job creatorsWASHINGTON, April 21, 2021 (GLOBE NEWSWIRE) -- Trade associations representing some of America’s top industries and employers today praised Representatives Al Lawson (FL-05) and Ken Buck (CO-04) for reintroducing the Aluminum Pricing Examination (APEX) Act (H.R. 2698), bipartisan legislation that would bring transparency to aluminum pricing and provide stability for American workers and job creators. “We applaud Representatives Lawson and Buck for continuing their bipartisan work to level the playing field and ensure unfair market practices do not disproportionately harm the American beer industry or the 2.1 million jobs it supports,” said Jim McGreevy, president and CEO of the Beer Institute. “The APEX Act will bring much-needed transparency to aluminum benchmark pricing, which helps all those in the beer industry and the multitude of American job creators that rely on aluminum.” The American economy has faced significant job losses and economic uncertainty due to the COVID-19 pandemic, and in 2020 alone, more than 568,000 jobs were lost in the beer industry. APEX would bring stability and transparency to the price of a major commodity used by American businesses, spurring long-term investment and creating new good-paying opportunities for American workers. This commonsense and bipartisan proposal to increase regulatory oversight would restore confidence in the metals market, ultimately benefiting American workers and the broader U.S. economy, including the millions of American consumers who purchase aluminum products every day. “America’s beverage companies appreciate this effort to bring transparency, enhanced oversight and more certainty to a complicated metals pricing system,” said Katherine Lugar, president and CEO of American Beverage. “We appreciate Mr. Lawson and Mr. Buck for continuing to lead the way on this bipartisan bill that will ultimately benefit American workers and consumers.” Almost one third of all non-alcoholic beverages come in aluminum cans, and more than 74% of all beer produced and sold in the United States is packaged in aluminum cans and aluminum bottles. Aluminum used in cans is the single most substantial cost in American beverage and beer manufacturing. According to a recent report by Harbor Aluminum, from March 2018 through December 2020, the Section 232 tariffs cost America’s beverage industries an additional $848.6 million. The tariffs have created significant costs on aluminum end-users, and these costs are only magnified by the problem inherent in the current aluminum pricing structure. When the tariffs are coupled with the effects of the pandemic, American businesses are faced with enormous costs and American jobs and future investment are imperiled. Aluminum boats, for example, represent more than 40 percent of new boat sales each year and account for approximately $3 billion in retail sales. An estimated 22,000 American jobs rely on the aluminum sector of the marine industry, which has seen its aluminum prices spike, even for domestically produced aluminum. Further, marine manufacturers are not only suffering from inflated prices due to 232 tariffs but also retaliatory European Union tariffs on American-made boats and engines that have decreased U.S. exports to the E.U. by 42 percent. “Section 232 tariffs have been weighing on the recreational boating industry since 2018, specifically, driving up the cost of critical raw materials and reducing annual exports to Europe by more than 40 percent – a market that previously accounted for a quarter of the industry’s international sales,” said Frank Hugelmeyer, president of the National Marine Manufacturers Association. “These aluminum and steel tariffs have caused far more harm than any perceived benefits and will lead to significant job losses across multiple sectors of the economy if they are not removed in short order.” Aluminum is also a critical component in flexible packaging not only to maintain product freshness and safety but also to offer stiffness, integrity and sterility to the package. Aluminum foil is used in flexible packaging for many of the products that consumers purchase every day, whether in grocery stores, pet stores, retail stores, or pharmacies, as it is used for a variety of purposes, including food, beverage, and medical and pharmaceutical applications. Products in flexible packaging are also found in doctors’ offices, hospitals, and restaurants. When it comes to packaging for medical devices, food, and pharmaceuticals, quality is critical – literally a matter of life and death. “Fine gauge aluminum foil is necessary for barrier protection and sterility in a host of food, pharmaceutical and medical device flexible packaging, and it is not available in the U.S. both in terms of quantity or quality. The Midwest Premium, on top of the current tariffs and duties on foil from outside the country, leaves U.S. converters vulnerable to competition from foreign suppliers of finished goods. In fact, these extra costs only injure the aluminum manufacturers’ customers and may destroy the very market they seek to protect,” said Alison Keane, president and CEO of the Flexible Packaging Association. H.R. 2698 is similar to H.R. 1406 and S. 1953, bipartisan and bicameral legislation introduced in the 116th Congress. ### About the Beer Institute The Beer Institute is a national trade association for the American brewing industry, representing brewers of all sizes, as well as beer importers and industry suppliers. First founded in 1862 as the U.S. Brewers Association, the Beer Institute is committed today to the development of sound public policy and to the values of civic duty and personal responsibility. For additional updates from the Beer Institute, visit our website, follow @BeerInstitute on Twitter, like the Beer Institute on Facebook, and follow the Beer Institute on Instagram. About American Beverage American Beverage is the national trade organization representing the broad spectrum of companies that manufacture and distribute non-alcoholic beverages in the United States. Our member companies directly employ nearly a quarter-million people and have a direct economic impact of $169.7 billion. For more information, please visit www.balanceus.org and http://www.ameribev.org/. About the National Marine Manufacturers Association The National Marine Manufacturers Association (NMMA) is dedicated to advocating for and promoting the strength of marine manufacturing, the sales and service networks of its members, and the boating lifestyle. NMMA is the nation’s leading trade association representing boat, marine engine and accessory manufacturers. Collectively, NMMA members manufacture an estimated 80 percent of marine products used in North America. NMMA is a unifying force and powerful voice for the recreational boating industry, working to strengthen and grow boating and protect the interests of its member companies. For more information, please visit www.nmma.org About the Flexible Packaging Association The Flexible Packaging Association is the voice of the U.S. manufacturers of flexible packaging and their suppliers. The association’s mission is connecting, advancing, and leading the flexible packaging industry. Flexible packaging represents over $33 billion in annual sales in the U.S. and is the second largest and one of the fastest growing segments of the packaging industry. Flexible packaging is produced from paper, plastic, film, aluminum foil, or any combination of those materials, and includes bags, pouches, labels, liners, wraps, rollstock, and other flexible products. Learn more at www.flexpack.org and www.perfectpackaging.org. CONTACT: Alex Davidson Beer Institute firstname.lastname@example.org William M. Dermody Jr. American Beverage email@example.com John-Michael Donahue National Marine Manufacturers Association firstname.lastname@example.org Dani Diehlmann Flexible Packaging Association email@example.com
David Barksdale, Norton Rose Fulbright Los Angeles, April 21, 2021 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright today announced that three real estate lawyers, led by partner David Barksdale, have joined its Los Angeles office. Senior counsel Kevin Garland and associate Joseph Bini accompany Barksdale in the move from Loeb & Loeb. With more than 30 years of real estate finance and investment experience, Barksdale represents lenders and borrowers in structured and syndicated finance transactions, and handles acquisitions, dispositions, leasing, workouts and restructurings involving real estate assets. The 10th lateral partner to join Norton Rose Fulbright in California over the last 20 months, he also advises special servicers, lenders and investors in the workout and restructuring of real estate financing. Garland represents lenders making loans, whether acquisition, construction, or permanent, which are secured by real estate. He has experience closing acquisitions, dispositions, joint ventures, borrower-side financings and sale-leaseback transactions.Bini represents banks, institutional investors, sponsors and borrowers in syndicated and single lender complex debt financing transactions. His work includes secured and unsecured asset-based lending facilities, real estate secured loans, construction loans and acquisition finance.Jeff Cody, Norton Rose Fulbright's US Managing Partner, said:“The addition of Dave, Kevin and Joe to our Los Angeles office reinforces the firm’s commitment and investment in our real estate practice and overall presence in California. This team possesses extensive real estate law experience and a tremendous client base. We are delighted that Dave, Kevin and Joe have joined the firm.”John Jennings, Norton Rose Fulbright’s US Head of Real Estate, commented:“This exceptional group of lawyers is a fantastic addition to the firm’s real estate group, which has been advising our clients through the uncertainty of the pandemic. With Dave’s arrival, our firm will be renewing and expanding its focus on distressed real estate featuring a cross-disciplinary team to assist our clients with the most complex of issues.”Barksdale, who is a Fellow of the American College of Real Estate Lawyers and a member of the CRE Finance Council, said:“I have long admired Norton Rose Fulbright’s global reach, which will benefit my clients tremendously. The firm’s substantial presence in the Northeast will afford Kevin, Joe and me the opportunity and resources to continue expanding our coast to coast practice, as New York is a key market for real estate finance.”Barksdale, who is admitted to practice in California and Nevada, earned his BA and BS from Oral Roberts University and his law degree from the University of California Hastings College of Law. Garland, who is licensed to practice in California, Illinois and Delaware, earned his BA from the University of Washington and his law degree from American University Washington College of Law. Bini, who is licensed to practice in California, earned his BA from Boston College and his law degree from the University of California at Los Angeles School of Law. Notes for editors: Norton Rose Fulbright Norton Rose Fulbright is a global law firm providing the world’s preeminent corporations and financial institutions with a full business law service. The firm has more than 4,000 lawyers and other legal staff based in Europe, the United States, Canada, Latin America, Asia, Australia, Africa and the Middle East. Recognized for its industry focus, Norton Rose Fulbright is strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare. Through its global risk advisory group, the firm leverages its industry experience with its knowledge of legal, regulatory, compliance and governance issues to provide clients with practical solutions to the legal and regulatory risks facing their businesses. Norton Rose Fulbright operates in accordance with its global business principles of quality, unity and integrity, aiming to provide the highest possible standard of legal service in each of its offices and to maintain that level of quality at every point of contact. Norton Rose Fulbright Verein, a Swiss verein, helps coordinate the activities of Norton Rose Fulbright members but does not itself provide legal services to clients. Norton Rose Fulbright has offices in more than 50 cities worldwide, including London, Houston, New York, Toronto, Mexico City, Hong Kong, Sydney and Johannesburg. For more information, see nortonrosefulbright.com/legal-notices. Law around the worldnortonrosefulbright.com Attachment david_barksdale_master_April5 CONTACT: Dan McKenna Norton Rose Fulbright 713-651-3576 firstname.lastname@example.org
Tangled up in Bob Dylan biographer’s attack. Clinton Heylin | European Super League | Psychedelics | The Guardian